Zevra Therapeutics (NASDAQ:ZVRA) Posts Quarterly Earnings Results, Beats Estimates By $0.14 EPS

Posted by George Bondi on Aug 7th, 2026

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.14, FiscalAI reports. Zevra Therapeutics had a net margin of 42.82% and a return on equity of 58.95%. The business had revenue of $39.66 million for the quarter, compared to analysts’ expectations of $33.88 million.

Here are the key takeaways from Zevra Therapeutics’ conference call:

Second-quarter revenue rose 53% year over year to $39.7 million, driven by $30.2 million in U.S. MIPLYFFA sales, which increased 23% sequentially and 40% year over year.
MIPLYFFA enrollment reached 184 prescription forms through June 30, including 23 in the first half of 2026, with a diverse mix of newly and previously diagnosed patients, children and adults, and specialty-center and community-practice prescribers.
Zevra requested an EMA re-examination of arimoclomol’s negative CHMP opinion and expects a decision in the fourth quarter; management cited long-term, pediatric, expanded-access, and safety data as support, but approval remains uncertain.
Celiprolol’s Phase III DISCOVER trial remains early and event-driven, with 66 of 150 patients enrolled and only three confirmed events versus the 28 needed for interim analysis, prompting efforts to accelerate enrollment and regulatory discussions.
Cash, cash equivalents, and investments totaled $260.2 million at quarter-end, up approximately $23.4 million sequentially, giving Zevra flexibility to fund MIPLYFFA expansion, celiprolol, and potential external opportunities without relying on capital markets.

Zevra Therapeutics Stock Up 12.8%

Shares of NASDAQ:ZVRA opened at $11.88 on Friday. The firm has a market cap of $702.35 million, a P/E ratio of 12.91 and a beta of 0.91. Zevra Therapeutics has a 12-month low of $7.16 and a 12-month high of $15.03. The business has a fifty day simple moving average of $12.32 and a 200 day simple moving average of $10.57.

Analysts Set New Price Targets

A number of research analysts have recently commented on ZVRA shares. Cantor Fitzgerald increased their target price on shares of Zevra Therapeutics from $24.00 to $34.00 and gave the stock an “overweight” rating in a report on Monday, June 8th. UBS Group reiterated a “buy” rating on shares of Zevra Therapeutics in a research report on Wednesday, June 24th. HC Wainwright reissued a “buy” rating and issued a $26.00 price objective on shares of Zevra Therapeutics in a research note on Tuesday, June 23rd. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a report on Thursday. Finally, Canaccord Genuity Group dropped their target price on Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating for the company in a research report on Monday, July 27th. Nine research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $27.29.

Read Our Latest Stock Report on ZVRA

Key Headlines Impacting Zevra Therapeutics

Here are the key news stories impacting Zevra Therapeutics this week:

Positive Sentiment: Q2 earnings and revenue exceeded expectations. Zevra reported $39.7 million in second-quarter revenue, up 53% year over year and above the roughly $34 million consensus estimate. EPS of $0.25 also surpassed analyst expectations of approximately $0.08–$0.11. MIPLYFFA generated $30.2 million in revenue, supporting the company’s commercial growth. Zevra Therapeutics Q2 earnings article
Positive Sentiment: Cash generation and financial flexibility improved. The company reported a strong cash position of $260.2 million and positive operating execution, giving it additional resources to support MIPLYFFA commercialization and future development programs. Zevra Q2 2026 financial results and corporate update
Positive Sentiment: Regulatory and patent updates strengthened the MIPLYFFA outlook. Zevra expects a European Commission CHMP reexamination opinion in the fourth quarter, while MIPLYFFA’s Orange Book listing has been extended to 2041. The developments may improve visibility around potential European approval and provide longer U.S. market exclusivity. Zevra CHMP reexamination and Orange Book update
Positive Sentiment: Citizens JMP raised its price target to $28 from $25 and maintained a “market outperform” rating. The new target is well above the recent trading level and reinforces bullish analyst sentiment; several analysts have targets in the mid-$20s to mid-$30s. Benzinga analyst price target report
Neutral Sentiment: Institutional positioning was mixed, with some funds adding shares and others reducing or exiting positions. This suggests continued disagreement about Zevra’s valuation and execution outlook.
Negative Sentiment: Recent insider activity showed sales by executives and no reported insider purchases over the past six months. While these transactions do not necessarily reflect business fundamentals, they may temper investor enthusiasm.

Hedge Funds Weigh In On Zevra Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company lifted its holdings in shares of Zevra Therapeutics by 9.4% in the second quarter. The Manufacturers Life Insurance Company now owns 20,294 shares of the company’s stock valued at $179,000 after purchasing an additional 1,750 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Zevra Therapeutics by 6.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company’s stock valued at $238,000 after buying an additional 1,812 shares during the last quarter. Deutsche Bank AG boosted its holdings in Zevra Therapeutics by 4.4% during the 4th quarter. Deutsche Bank AG now owns 45,939 shares of the company’s stock worth $412,000 after acquiring an additional 1,936 shares during the last quarter. MetLife Investment Management LLC grew its stake in shares of Zevra Therapeutics by 10.5% in the 4th quarter. MetLife Investment Management LLC now owns 27,867 shares of the company’s stock worth $250,000 after acquiring an additional 2,653 shares in the last quarter. Finally, Federated Hermes Inc. raised its holdings in shares of Zevra Therapeutics by 17.8% in the fourth quarter. Federated Hermes Inc. now owns 23,453 shares of the company’s stock valued at $210,000 after purchasing an additional 3,539 shares during the last quarter. 35.03% of the stock is currently owned by institutional investors.

Zevra Therapeutics Company Profile

(Get Free Report)

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.